William S. Dalton, Ph.D., M.D.
Founder & Chief Executive Officer
Dr. William (Bill) S. Dalton serves as Founder & CEO of M2Gen®, a national biotechnology subsidiary of Moffitt Cancer Center. In addition to being known for his cancer research, Dr. Dalton is regarded as a health policy expert interested in the study and development of the most effective approaches to cancer research and care. He currently serves as the President of the Association of American Cancer Institutes, Chairs the Science Policy & Legislative Affairs Committee of the American Association for Cancer Research, as well as serves on the Institute of Medicine’s National Cancer Policy Forum and various NCI, cancer center and research foundation scientific advisory boards across the U.S. In addition, Dr. Dalton serves at the state level as a member of the Florida Council of 100, an advisory role to the Governor, the Chief Justice, the Legislature, as well as private organizations, to promote the economic growth of Florida and improve the economic well-being and quality of life of the citizens of Florida.
Dr. Dalton’s basic and translational research interests focus on molecular mechanisms of drug resistance and new drug discovery, and he has over 200 publications, several patents, and has been NIH funded since 1985. Dr. Dalton is also interested in the development of personalized cancer care and patient-centered outcomes research through Moffitt’s nationally renowned Total Cancer Care™ approach to developing evidence-based, personalized cancer treatments and information/decision tools for patients and clinicians. Total Cancer Care includes one of the largest cancer tumor bio-repositories and data warehouses in the U.S. dedicated to the development of personalized medicine. For his leadership in this area, Dr. Dalton was recognized as the 2010 recipient of the Personalized Medicine Coalition’s National Leadership in Personalized Medicine Award.